反射式共聚焦显微镜引导二氧化碳激光消融低危基底细胞癌的前瞻性研究
本研究前瞻性纳入经活检证实的低危基底细胞癌(BCC)病灶,在消融前后用反射式共聚焦显微镜(RCM)成像,若发现残留肿瘤则追加激光扫描。22处病灶中5处(22.7%)在首次消融后即刻经RCM发现残留肿瘤;中位随访28.5个月未见复发。提示RCM可辅助激光消融流程、提高疗效。
要点
- RCM可在激光消融后即刻识别亚临床残留肿瘤,指导追加扫描
- 22处低危BCC首次消融后RCM检出残留5处(22.7%)
- 中位随访28.5个月未见复发,支持该流程可行性
核心结论
- 在激光消融流程中加入RCM可检出首次消融后的亚临床持续肿瘤,可能有助于提高激光消融的疗效。
研究设计与样本
- 前瞻性研究,纳入经活检证实的低危基底细胞癌病灶,消融前后行RCM成像。
- 共22处肿瘤部位、9例患者(5男4女),中位年龄59±12.9岁(范围30-74岁),平均肿瘤大小7.7 mm(范围5-10 mm)。
主要发现
- 22处病灶中5处(22.7%)在首次消融后即刻经RCM发现残留肿瘤,并追加激光扫描。
- 中位随访28.5个月(范围22-32个月),未发现复发。
临床怎么用
- 对低危BCC行CO2激光消融时,可在首次消融后用RCM即时评估有无残留肿瘤并追加扫描。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Basal cell carcinoma (BCC) treatment modalities can be stratified by tumor subtype and recurrence risk. The main limitation of nonsurgical treatment modalities is the lack of histopathologic confirmation. Reflectance confocal microscopy (RCM) is a noninvasive imaging device that provides quasihistologic images. OBJECTIVE: To evaluate the feasibility and efficacy of RCM-guided carbon dioxide (CO2) laser ablation of low-risk BCCs. METHODS: Prospective study with biopsy specimen-proven low-risk BCCs imaged with RCM. RCM was performed on these sites before and after ablation. If residual tumor was found, a new series of laser passes were performed. The patients were then monitored for recurrence clinically and with RCM. RESULTS: Twenty-two tumor sites in 9 patients (5 men, 4 women) were imaged and treated. Median age was 59 ± 12.9 years (range, 30-74 years). Mean tumor size was 7.7 mm (range, 5-10 mm). Residual tumor was identified in 5 of 22 cases (22.7%) under RCM on immediate first-pass postablation sites, prompting additional laser passes. Median follow-up was 28.5 months (range, 22-32 months) with no recurrences found. CONCLUSIONS: Addition of RCM to laser ablation workflow can detect subclinical persistent tumor after initial ablation and may serve as an aid to increase the efficacy of laser ablation.
引用
- Navarrete-Dechent C, Cordova M, Liopyris K, et al. Reflectance confocal microscopy-guided carbon dioxide laser ablation of low-risk basal cell carcinomas: A prospective study. J Am Acad Dermatol. 2019. PMID: 31202871. doi:10.1016/j.jaad.2019.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。